Literature DB >> 9533762

Transport of glutathione conjugates into secretory vesicles is mediated by the multidrug-resistance protein 1.

M J Van Luyn1, M Müller, J Renes, C Meijer, R J Scheper, E F Nienhuis, N H Mulder, P L Jansen, E G De Vries.   

Abstract

Intracellular glutathione-conjugate transport was evaluated in the human small cell lung carcinoma cell line GLC4 with low multidrug resistance protein (MRP1) expression and its 300x doxorubicin-resistant, MRP1-over-expressing, GLC4-Adr subline. Transport of non-toxic concentrations of monochlorobimane and 5-chloro-methyl fluorescein diacetate was evaluated using fluorescence microscopy. After exposure to these compounds, fluorescence was observed especially in intracellular vesicles in GLC4-Adr. Immunotransmission electron microscopy showed that MRP1 was present in the vesicle membranes and plasma membrane, while inside the vesicles the glutathione conjugate of 1-chloro-2,4-dinitrobenzene could be detected. Experiments with brefeldin A, which induces arrest in vesicle release from the Golgi complex, indicated that these vesicles may originate from the trans-Golgi network. In GLC4-Adr cells, doxorubicin also was transported in vesicles, with an arrest in vesicle release from the Golgi complex. Our results indicate that MRP1 functions as a glutathione-conjugate transporter not only at the plasma membrane but also in intracellular secretory vesicles.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9533762     DOI: 10.1002/(sici)1097-0215(19980330)76:1<55::aid-ijc10>3.0.co;2-f

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1.

Authors:  J Renes; E G de Vries; E F Nienhuis; P L Jansen; M Müller
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

Review 2.  Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1).

Authors:  Eva Bakos; László Homolya
Journal:  Pflugers Arch       Date:  2006-12-23       Impact factor: 3.657

3.  Multidrug Resistance-associated Protein-1 (MRP-1)-dependent Glutathione Disulfide (GSSG) Efflux as a Critical Survival Factor for Oxidant-enriched Tumorigenic Endothelial Cells.

Authors:  Gayle M Gordillo; Ayan Biswas; Savita Khanna; James M Spieldenner; Xueliang Pan; Chandan K Sen
Journal:  J Biol Chem       Date:  2016-03-09       Impact factor: 5.157

Review 4.  Glutathione efflux and cell death.

Authors:  Rodrigo Franco; John A Cidlowski
Journal:  Antioxid Redox Signal       Date:  2012-07-16       Impact factor: 8.401

5.  Formation and rapid export of the monochlorobimane-glutathione conjugate in cultured rat astrocytes.

Authors:  Jens Waak; Ralf Dringen
Journal:  Neurochem Res       Date:  2006-11-07       Impact factor: 3.996

6.  The role of the VPS4A-exosome pathway in the intrinsic egress route of a DNA-binding anticancer drug.

Authors:  Vivien Y Chen; Maria M Posada; Levi L Blazer; Tong Zhao; Gus R Rosania
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

7.  Subcellular localization and activity of multidrug resistance proteins.

Authors:  Asha Rajagopal; Sanford M Simon
Journal:  Mol Biol Cell       Date:  2003-04-17       Impact factor: 4.138

8.  Assessment of golgi apparatus versus plasma membrane-localized multi-drug resistance-associated protein 1.

Authors:  Allyn M Kaufmann; Alana J Toro-Ramos; Jeffrey P Krise
Journal:  Mol Pharm       Date:  2008-06-17       Impact factor: 4.939

9.  The exposure of cancer cells to hyperthermia, iron oxide nanoparticles, and mitomycin C influences membrane multidrug resistance protein expression levels.

Authors:  Karolin Franke; Melanie Kettering; Kathleen Lange; Werner A Kaiser; Ingrid Hilger
Journal:  Int J Nanomedicine       Date:  2013-01-20

10.  Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation.

Authors:  R Boonstra; H Timmer-Bosscha; J van Echten-Arends; D M van der Kolk; A van den Berg; B de Jong; K D Tew; S Poppema; E G E de Vries
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.